2026-04-13T14:24:06Zhttps://recercat.cat/oai/request

oai:recercat.cat:2117/3369922026-01-30T08:25:35Zcom_2072_1033col_2072_452950

00925njm 22002777a 4500 dc Sepúlveda, Maria author Llufriu, Sara author Martínez-Hernández, Eugenia author Català Sabaté, Martí author Artola, Montse author Hernando, Ana author Montejo, Carmen author Pulido-Valdeolivas, Irene author Martinez-Heras, Eloy author Guasp, Mar author Solana, Elisabeth author Llançó, Laura author Escudero, Domingo author Aldea, Marta author Prats Soler, Clara author Graus Ribas, Francesc author Blanco, Yolanda author Saiz, Albert author 2021-01-27 Objective: To investigate the incidence of coronavirus disease 2019 (COVID-19) in a single-center cohort of patients with MS and to explore the contribution of their comorbidities and therapies to the outcome. Methods: A cross-sectional mixed-method study was conducted involving an email-based, self-administered questionnaire sent on May 21, 2020, to 586 patients with MS followed at the MS Unit of Hospital Clinic, University of Barcelona, along with telephone interview, and review of electronic medical records until June 18, 2020. The cumulative incidence of confirmed COVID-19 (positive PCR or antibody test) and all COVID-19 cases (confirmed and suspected) from the start of the pandemic was compared with the population estimates for Barcelona. Results: A total of 407 patients (69.5%) completed the survey. Most of the responders (67%) were female. The responders had a median age of 48 years (range 19–86), relapsing-remitting disease (84%), at least 1 comorbidity (45%), and were on disease-modifying therapy (DMT; 74.7%). COVID-19 was confirmed in 5 patients (1.2%) and suspected in 46 (11.3%). The cumulative incidence of confirmed COVID-19 cases was similar to that of the general population but was almost 2-fold higher when all cases were considered (p < 0.001). Six patients (11.7%) were hospitalized, of which 5 had good recovery and 1 died. Hospitalized patients were more frequently male, had diabetes and had progressive forms of MS (p < 0.05). DMT was not associated with the risk of infection or the outcome. Conclusions: In the studied MS cohort, the incidence of COVID-19 was higher than that of the general population; however, most patients did not require hospitalization and had a good outcome despite the frequent presence of comorbidities and treatment with DMT. Peer Reviewed Postprint (published version) Àrees temàtiques de la UPC::Matemàtiques i estadística::Anàlisi numèrica::Modelització matemàtica Epidemics Multiscale modeling COVID-19 (Disease) Disease-modifying therapy Expanded disability severity scale SARS-CoV-2 Epidemies Modelització en etapes múltiples COVID-19 (Malaltia) Incidence and impact of COVID-19 in MS. A survey from a Barcelona MS Unit.